Kardigan filed for a U.S. IPO with three late-stage cardiovascular programs targeting genetic dilated cardiomyopathy, calcific aortic valve stenosis, and severe hypertension. The company said it plans to use proceeds to continue development across danicamtiv, ataciguat, and tonlamarsen, which are positioned in late-stage tracks where patients have limited approved options. The filing highlights renewed capital market activity for clinical-stage biotechs as investors seek defined regulatory paths and clearer de-risking milestones. For each asset, attention is on trial readouts and whether endpoints support progression to pivotal studies or approvals. Kardigan’s strategy also reflects a broader precision-medicine focus in cardiology—using molecularly targeted approaches to address specific disease mechanisms rather than symptom-based treatment.